Glyburide Healthy Volunteer Study

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
University of Maryland
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01716338
First received: October 12, 2012
Last updated: April 3, 2014
Last verified: April 2014
  Purpose

Glyburide is a medication that has been safely used for several decades to treat non-insulin dependent diabetes. This pilot study seeks to evaluate whether glyburide, administered at the lowest dose (1.5 mg/dL daily) to healthy (non-diabetic) subjects is safe both physically and cognitively. The investigators are hopeful that the results of this study will provide the necessary foundation to evaluate this medication's use on a larger scale to determine the feasibility of using glyburide in soldiers either prophylactically or for the treatment of brain injury.


Condition Intervention Phase
Healthy Volunteers
Drug: Glyburide
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Glyburide Healthy Volunteer Study

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    The primary objective of this study is to evaluate the safety of glyburide in healthy, non-diabetic volunteers while simulating strenuous activity to observe for any adverse events (i.e. hypoglycemia, dizziness, confusion, etc.). Neuropsychological testing, physical exams, vital signs, ECGs, cognitive assessments, and laboratory values (including serum glucose levels collected 4 x's per day and as needed) will be conducted throughout the 7 day in-patient study to assess for any adverse/serious adverse events.


Secondary Outcome Measures:
  • Cognitive impact [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Determine the impact after 7 days of glyburide 1.5mg daily (with breakfast) in healthy volunteers who are able to participate in scheduled strenuous activities and adhere to a structured meal plan on cognitive performance using a computer program to test cognition before study drug administration and at the end of the study in addition to daily physical examinations which include mini mental status exams.


Estimated Enrollment: 21
Study Start Date: January 2013
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Glyburide
1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
Drug: Glyburide
Other Names:
  • Micronase
  • Glybencamide
Placebo Comparator: Sugar Pill (Capsule)
Matching placebo capsule by mouth every day with breakfast for 7 days
Drug: Placebo
Other Name: Sugar Pill (capsule)

Detailed Description:

This study is a placebo controlled (2:1 drug vs. placebo), randomized clinical trial of 21 healthy, non-diabetic volunteers receiving daily doses of oral glyburide (1.5 mg) vs. placebo while under careful medical monitoring in an inpatient Clinical Research Unit (CRU)within the Center for Applied Research Sciences (CARS) at the Washington University in St. Louis Medical Center for a duration of 7 days and nights (24 hours per day). Interested subjects who call for more information about the study will be scheduled for a screening visit. Subjects will participate first in an informed consent process, and those wishing to take part will be asked to undergo a comprehensive interview detailing their past medical history and formal physical examination (which includes laboratory tests of the urine and blood). If a subject is deemed appropriate by the team, he/she will be asked to perform an exercise test (treadmill for 30 minutes) and will have an Electrocardiogram (ECG) completed to further determine eligibility. Individuals who do not meet inclusion criteria based on screening activities will be notified immediately that they are not eligible. Volunteers meeting all eligibility criteria will be scheduled for the week long in-patient evaluation.

Each subject will undergo a battery of physical, cognitive, and laboratory tests in addition to receiving oral glyburide or placebo each day for one week.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Volunteers between the ages of 18 and 40.
  • Have a Body Mass Index (BMI) between 18-30.
  • Normal screening physical examination (non-pregnant as confirmed by serum Beta HcG,non-diabetic as confirmed by normal Hgb A-1C, normal baseline ECG and vital signs, laboratory values within normal limits (the lab tests include: complete blood count, electrolytes, liver function tests, kidney function tests, uric acid, cholesterol, iron, urinalysis, urine drug screen; all are conducted within 2 weeks prior to randomization).
  • Women of Childbearing Potential (WCP) demonstrate a willingness to use contraception methods (other than birth control medications) to prevent pregnancy from time of consent to 30 days past last dose. **Note, birth control medications MAY BE used after completion of the inpatient hospital phase of the study (i.e. after discharge).
  • Unremarkable past medical history.
  • Ability to provide informed consent.
  • Ability to undergo physical exercise (determined through a treadmill exercise test to ensure physical fitness of participants). Those who experience fatigue, dizziness or chest pain during the screening exercise test on the treadmill will be excluded.
  • Ability to undergo neuropsychological test for attention, cognition, dexterity, etc.
  • Willing to remain in the in-patient setting for the duration of the study.

Exclusion Criteria:

  • Use of investigational drug within 4 weeks of study.
  • Using tobacco.
  • Acute illness or surgery within 4 weeks of study.
  • Allergic to sulfonylurea-related drugs.
  • Presence of pathological condition of any part of the body.
  • Any medication within 2 weeks of the study, including oral contraceptives.
  • Ingestion of alcohol or caffeine containing food or beverages within 48 hours of start of study.
  • History of alcohol or drug abuse, cardiac arrhythmias, psychotropic agent use, immunosuppressive condition (i.e. HIV, AIDS, Cancer) or hepatitis.
  • Donation of blood within 3 months or receiving blood products within 14 days.
  • Recent body tattoo or piercing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01716338

Locations
United States, Missouri
Washington University in St. Louis Clinical Research Unit (CRU)
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
University of Maryland
Investigators
Principal Investigator: Grant Bochicchio, MD, MPH Washington University School of Medicine
  More Information

No publications provided

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01716338     History of Changes
Obsolete Identifiers: NCT01157637
Other Study ID Numbers: A-15112.b
Study First Received: October 12, 2012
Last Updated: April 3, 2014
Health Authority: United States: Food and Drug Administration
United States: Department of Defense

Keywords provided by Washington University School of Medicine:
glyburide
glybenclamide
hypoglycemia

Additional relevant MeSH terms:
Glyburide
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 24, 2014